Interventional Devices & Therapies

Philips completes acquisition of The Spectranetics Corporation

Acquisition expands and strengthens Philips’ image-guided therapy business group

Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, announced that it has completed the acquisition of The Spectranetics Corporation (NASDAQ: SPNC), a U.S.-based global leader in vascular intervention and lead management solutions.

Spectranetics' device portfolio includes a range of catheters to treat coronary and peripheral artery disease, and the removal of implanted pacemaker and implantable cardioverter defibrillator leads. The Stellarex drug-coated balloon is a key growth driver in this portfolio. It is a next generation drug-coated balloon that provides proven peripheral artery disease treatment and is backed by robust clinical evidence. The Stellarex drug-coated balloon is CE-marked and recently obtained U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA).

Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has completed the acquisition of The Spectranetics Corporation(NASDAQ: SPNC), a U.S.-based global leader in vascular intervention and lead management solutions.

Spectranetics' device portfolio includes a range of catheters to treat coronary and peripheral artery disease, and the removal of implanted pacemaker and implantable cardioverter defibrillator leads. The Stellarex drug-coated balloon is a key growth driver in this portfolio. It is a next generation drug-coated balloon that provides proven peripheral artery disease treatment and is backed by robust clinical evidence. The Stellarex drug-coated balloon is CE-marked and recently obtained U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA).

Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has completed the acquisition of The Spectranetics Corporation(NASDAQ: SPNC), a U.S.-based global leader in vascular intervention and lead management solutions.

Spectranetics' device portfolio includes a range of catheters to treat coronary and peripheral artery disease, and the removal of implanted pacemaker and implantable cardioverter defibrillator leads. The Stellarex drug-coated balloon is a key growth driver in this portfolio. It is a next generation drug-coated balloon that provides proven peripheral artery disease treatment and is backed by robust clinical evidence. The Stellarex drug-coated balloon is CE-marked and recently obtained U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA).

Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has completed the acquisition of The Spectranetics Corporation(NASDAQ: SPNC), a U.S.-based global leader in vascular intervention and lead management solutions.

Spectranetics' device portfolio includes a range of catheters to treat coronary and peripheral artery disease, and the removal of implanted pacemaker and implantable cardioverter defibrillator leads. The Stellarex drug-coated balloon is a key growth driver in this portfolio. It is a next generation drug-coated balloon that provides proven peripheral artery disease treatment and is backed by robust clinical evidence. The Stellarex drug-coated balloon is CE-marked and recently obtained U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA).

View press release

Visit Spectranetics.com

Philips Image Guided Therapy

As the leader in image guided therapy, we are committed to working with healthcare providers to help improve treatment for every patient.

Our vision is to provide integrated solutions that advance minimally invasive procedures by helping healthcare providers to decide, guide, treat and confirm the right therapy for the right patient at the point of care. Working together to realize this vision, we can save and improve lives and reduce the total cost of care by making therapy more efficient, more appropriate and more personal.

We will help to ensure these solutions endure over time and continue to deliver value in the lab by providing the right in-lab support. These are the unique, specific capabilities that Philips Image Guided Therapy brings to our customers that will enable us to realize this vision together.

Peripheral

More
Cardiology

More
Advanced Imaging Systems

More

Lead Management

More

Introducing the

iFR Co-registration

technology

Only Philips co-registers iFR values directly onto the angiogram, allowing you to see precisely which parts of a vessel are causing ischemia.

Learn more

Cardiology

Philips is a global image guided therapy leader that provides solutions to help optimize and streamline PCI. We are committed to working with health care providers to improve treatment for every patient using our leading coronary IVUS, pressure and flow based technologies. Our integrated product offerings help clinicians decide, guide and confirm the right therapy for each patient at the point of care.

More

Peripheral

Discover the suite of products designed by Philips to help diagnose and treat peripheral disease. Review IVUS-guided stenting clinical evidence, access procedural tools, case reviews, and more. View our full line of peripheral vascular intervention strategies, tools and resources that can help you decide, guide, treat, and confirm.

More

Advanced Imaging Systems

Designed to power the future of precision guided therapy, Philips provides clarity in your approach and confidence in your results with a full suite of imaging and physiology analysis tools. With the choice of FFR, iFR and IVUS modalities on a single integrated platform, we deliver convenience in your workflow with true integration. IVUS and iFR co-registration are now available on the SyncVision advanced imaging system.

More